Company attributes
Location
Founder
Number of Employees (Ranges)
11 – 50
Email Address
care@juvlabs.com
Investors
Founded Date
2016
Total Funding Amount (USD)
238,300,000
Latest Funding Round Date
May 21, 2025
CFO
Latest Funding Type
Country
Headquarters
Investor attributes
Invested in
Other attributes
Company Operating Status
Active
Latest Funding Round Amount (USD)
76,000,000
Juvenescence Limited is a British Virgin Islands-based holding company that invests in human aging and longevity. They focus their investments and development on companies developing therapeutic strategies to treat the tissue-specific signature and pathologies of aging and senescence. The strategy includes products targeted at slowing cellular aging, slowing and reversing neurodegeneration, destroying senescent cells, replacing aging organs and editing patient genes.
Investment
Juvenescence has invested in LyGenesis, Souvien Therapeutics, BYOMass, BHB Therapeutics, AgeX Therapeutics, Napa Therapeutics, FoxBio, Insilico Medicine, GenerAIt Pharmaceuticals and Netrapharma.
Timeline
No Timeline data yet.
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
No Further Resources data yet.
